leadf
logo-loader
viewImugene Limited
(
ASX:IMUOTC:IUGNF
)

Imugene adds key members to its scientific advisory board to advance company forward

Imugene Ltd (ASX:IMU) CEO Leslie Chong sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Imugene is an Australian biotechnology company with operations in the U.S. and in Europe, developing cancer immunotherapies targeting B-cell peptide vaccines.

Quick facts: Imugene Limited

Follow
ASX:IMU

Price: 0.495 AUD

Market Cap: $2.7 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Imugene's Leslie Chong welcomes strong support for its $90 million placement

Imugene Ltd's Leslie Chong speaks to Proactive's Andrew Scott following the news of a $90 million placement to new and existing institutional and sophisticated investors as well as a share purchase plan for existing eligible shareholders to raise up to a further $5 million. She says the capital...

on 07/28/2021

2 min read